🔎 Today’s Daily Sift: Longevity Longevity just crossed a psychological frontier. Not “live forever” fantasy. Actual institutional momentum. The healthspan economy is merging AI, pharmaceuticals, preventative diagnostics, and consumer wellness into a single operating system for the human body. This week’s biggest signal is the convergence of GLP 1 therapies, peptide experimentation, biological age diagnostics, and AI driven preventative care. Investors are shifting away from immortality narratives and focusing on extending productive years while compressing disease burden. That changes everything. The most important scientific development remains the FDA cleared human trial from Life Biosciences involving partial epigenetic reprogramming using Yamanaka factor based gene therapy. In plain English: Scientists are now attempting to biologically reset damaged human cells in living patients. The Overton window around aging is moving fast. At the same time, new longevity trials a...